News 

August 8, 2019

Ibex announces publication of PCBP1 patent pending

The present disclosure provides compositions and methods of using gene therapy to decrease cell migration and metastasis and reduce tumor mass or burden. The methods disclosed herein employ plasmids, vectors, and non-viral vectors that contain PCBP1 and/or PCBP1 mutants which inhibit the expression of cancer biomarkers and decrease cell migration or tumor size.   https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019153008

September 20, 2017

Ibex announces SBIR award

Ibex Biosciences will continue to develop anti-MIF VHH antibodies by establishing larger production levels of the VHH and testing them in animal models. Our work will start with construction and expression of anti-MIF VHH and VHH-Fc antibodies. Succeeding feasibility work will focus on their characterization and demonstration of their functional antibody binding in cell line and animal models. While MIF has been demonstrated to play significant roles in many oncologic conditions, this evaluation will focus on prostate cancer for initial proof of concept. Subsequent development efforts will expand to other solid tumors such as pancreatic, lung, and others.   http://grantome.com/grant/NIH/R43-CA224732-01

February 2, 2017

Ibex announced as finalist

Immunomic Therapeutics, Inc., a privately-held, Maryland-based biotechnology company, today announced the finalists for their Cancer Discovery Incubator Award.  https://www.businesswire.com/news/home/20170202005259/en/Maryland-Cancer-Discovery-Incubator-Finalists-Announced

Copyright © 2017-2019 Ibex Biosciences, LLC